

RECEIVED  
CENTRAL FAX CENTER

01/23/2004 17:33 FAX 7043316090

ALSTON BIRD LLP

JAN 23 2004

001

**OFFICIAL**

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

## ALSTON & BIRD LLP

101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
704-444-1000  
Fax: 704-444-1111

### TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

**Date:**

January 23, 2004

**Recipient:**

Examiner Leigh C. Maier

**Company:**

U.S. PATENT & TRADEMARK  
OFFICE

**Fax Number:**

(703) 872-9306

**Voice Number:**

**Sender:**

Raymond O. Linker, Jr.

**Message:**

Application No. 10/069,913

OFFICIAL NON-FINAL RESPONSE

Number of Pages: (including cover page) **3**

**IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT.**

USER CODE:	LINKR	REQUESTED BY:	Jan Sherrill - 1163
CLIENT/MATTER:	033339/244859	OPERATOR:	

Alston & Bird

JAN 23 2004

OFFICIAL  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/069,913 Confirmation No.: 7074  
Applicant(s): Collic-Jouault et al.  
Filed: 02/28/2002  
Art Unit: 1623  
Examiner: Leigh C. Maier  
Title: USE OF A LOW MOLECULAR WEIGHT SULPHATED POLYSACCHARIDE  
TO OBTAIN A MEDICINE WITH ANTITHROMBOTIC ACTIVITY

Docket No.: 033339/244859  
Customer No.: 00826

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE

Sir:

In response to the Communication dated December 29, 2003, reconsideration by the Examiner is respectfully requested.

In the Official Action, the Examiner has taken the position that the original claims were directed to a method of preparing a medicinal product, and that the claims as presented in the previous amendment have been amended in such a way that they are now directed to an invention that is independent or distinct from the invention originally claimed.

We submit that the Examiner is mistaken in holding that the original claims were directed to a method of preparing a medicinal product. The claims as originally filed were "use claims" and not method claims. They were written in such a way as to be proper under European practice (Swiss-type claims) because therapeutic treatments are not patentable in the form of method claims according to European practice. Because this type of claim is not acceptable under United States practice, the claims were amended to recite a method of treatment, which is acceptable under United States practice.

However, the subject matter of the claimed invention has not changed, and the present claims are directed to the same technical feature as the originally-submitted use claims.

It should be noted that since the present application is a Section 371 application based upon a PCT application, the PCT unity of invention standards are applicable. Since the present

Appl. No.: 10/069,913  
Filed: February 28, 2002  
Page 2


claims are directed to the same technical feature as the originally-submitted use claims, there is no basis for the Examiner to hold that there is a lack of unity of invention and that a constructive election has occurred.

In order to substantiate an election or restriction requirement, the Examiner must provide a proper basis for such a requirement. The Official Action gives no reasons or analysis to substantiate a lack of unity of invention. Therefore, the holding of constructive election is without any proper basis, and should be withdrawn.

For the reasons noted, Applicants request the Examiner to vacate the previous Official Action and to issue an action on the merits of Claims 1-12 as now presented.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,



Raymond O. Linker, Jr.  
Registration No. 26,419

Customer No. 00826  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Charlotte Office (704) 444-1000  
Fax Charlotte Office (704) 444-1111  
CLT01/4629171v1

**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the U. S. Patent and Trademark Office at Fax No. (703) 872-9306 on the date shown below.

  
Janet F. Sherrill

January 23, 2004  
Date